This double-blind, randomized study was designed to evaluate the use of indomethacin (Indocid®, MSD) following caesarean delivery performed under spinal anaesthesia. Thirty ASA 1-II women presenting for elective caesarean were recruited. Spinal anaesthesia was performed in a standard manner using hyperbaric bupivacaine, fentanyl and morphine. At the completion of surgery, subjects were administered two rectal suppositories, followed by 12-hourly suppositories for six doses (three days). The study group received 100 mg indomethacin suppositories and controls were given placebo (Anusol®).
Indomethacin has been shown to have an opioidsparing effect after major surgery'-3, although little research has been done on its usefulness following caesarean delivery. This may stem from concern about uterine relaxation in the post partum period, and drug excretion into breast milk.
Indomethacin's anti-prostaglandin action may be useful in the management of discomfort from uterine cramps following delivery, in addition to its analgesic activity. This prospective, randomized, double-blind study was designed to examine the effectiveness of rectal indomethacin as an adjunct to subarachnoid opioid analgesia after caesarean delivery.
METHODS
After obtaining approval from the Hospital and University Ethics Committees, 30 ASA 1-11 women presenting for elective caesarean were approached for inclusion in the study. Informed consent was obtained. Women with diabetes, a history of asthma, or intolerance to non-steroidal anti-inflammatory agents (NSAIDs) were excluded.
After routine fluid pre-Ioading with 1000-2000 ml of warmed crystalloid, spinal anaesthesia was performed in a standardized manner at L2/3 or L3/4 with subjects either sitting or in the right lateral position. A 25 gauge Whitacre needle was used to administer a subarachnoid mixture of hyperbaric 0.75070 bupivacaine 1.2-1.4 ml, preservative-free morphine 250-300 p.g and fentanyl 10-15 p.g. The incision in all cases was transverse lower abdominal (Pfannenstiel).
At the completion of surgery, during transfer to the operating room stretcher, subjects were administered two rectal suppositories, followed by one suppository twice-daily for three days (Le. six more doses, a total of eight). This is the regimen used in a previous study3 and is intended to provide a loading dose of indomethacin, followed by regular rectal administration to allow absorption in the postoperative period. As with the previous study, indomethacin administration was ceased after three days to minimize gastrointestinal side-effects. Subjects, anaesthetists, surgeons and nurses were blind to the content of the suppositories, which were supplied by a pharmacist who followed a previously-constructed randomization table.
The study group received indomethacin 100 mg suppositories (i.e. 200 mg immediately, 100 mg twicedaily thereafter), while controls received Anusol®, a haemorrhoidal preparation containing zinc oxide, balsam and benzyl benzoate. In keeping with hospital policy, subjects were encouraged to request oral analgesia as soon as required, in the form of codeine 30 mg and paracetamol 325 mg (Tylenol 3 ®), on a three-hourly pm basis. Parenteral opioids were available if requested.
Pain scores using VAS were collected daily on days one to three, i.e. for 72 hours. A ten-centimetre ruler was used with "no pain" at one end and "worst pain imaginable" at the other. Emphasis was placed on delineating the three major components of postcaesarean pain, notably incisional, visceral and uterine pain. Subjects were asked to rate their pain at rest for "pain in the skin, where you've been cut", "pain deep inside, where your muscles have been pulled about" and "cramping pain, like period pain", respectively. Separate VAS scores were recorded for each component. Pain on movement was recorded separately, as was worst pain for the preceding 24 hours, since a score at a given moment might not have truly reflected the fluctuations in pain over a 24-hour period.
Time to first analgesia (TTFA), total oral analgesic consumption, duration of oxytocin infusion, and VAS for worst itch and worst nausea, were all recorded. Vaginal blood loss was recorded daily by midwives attending the mothers and recorded as light, moderate or heavy, according to inspection of pads.
Normally distributed data were summarized by means and standard deviations and analyzed with unpaired t-tests. Non-normally distributed data were expressed as medians and ranges and analyzed with Mann-Whitney tests. Data that were discrete categories were analyzed with Fisher's exact test. Many VAS scores were recorded as zeros, particularly on days 2 and 3, and so were collapsed into counts of yes or no and analyzed using Fisher's exact test. Only pain on movement VAS was normally distributed on all three days; this was analyzed with a two-factor repeated measures (RM) ANOVA.
Post-hoc comparisons for analyzing treatment and time factors were done using Newman-Keul's test. T tests with Bonferroni's correction applied were performed to compare the two treatment groups at each time point. Bonferroni's correction was also applied to each of the cutoff points for the variables measured over time, to adjust for mUltiple comparisons.
P<0.0166 was considered significant for all variables measured over three days. P < 0.05 was considered significant for all the other variables. Power calculations performed before the study began showed that 17 patients in each group were needed to achieve a power of 80070 (cc = 0.05), assuming a mean VAS of 5 ± 1 cm in the control placebo and 4 cm in the indomethacin group.
RESULTS
The two groups were comparable in terms of age, height, weight, parity, and duration of oxytocin infusion (Table I ). The height of the block in the study group ranged from TI-T5 and in the control group from T2-T5 ( Table 2 ). The volume of bupivacaine ranged from 1.2-1.4 ml for both groups (no statistically significant difference). Most of the subjects received 250 Jlg of subarachnoid morphine, with two in group 1 and three in group 2 receiving 300 Jlg. Median time to first request for oral analgesia was much greater in women who had received indomethacin: 39.6 hours (range 7-82) v. 9 hours (2-76) (P<0.003) ( Table 3 ). Median total additional analgesic requests for prescribed oral medication during the 72 hour study period were less in women receiving indomethacin: 4 (range 0-11) v. 11 (1-20) (P<0.0009) ( Table 4 ). No requests for parenteral analgesia were made. There was a highly significant difference between groups in terms of pain on movement VAS on day 1 (1.4± 1.2 v. 5.1 ±2.1, P< 0.00001) and non-significant differences persisted on days 2 (3.3 ±2 v. 5.5 ±2.9, P=0.027) and 3 (2.8±1.7 v. 4.5±2.7, P=0.066) ( Figure  1 ). Repeated Measures ANOVA for pain on movement showed a highly significant group effect, with the control group having higher mean pain VAS at all times compared with the indomethacin group (P<0.OO03). In the control group, there were no differences between days 1, 2 or 3. By comparison, the VAS scores on day 1 for the indomethacin group were much lower and there was a significant rise on day 2, maintained on day 3.
There was a highly significant difference in worst pain on day 1 (indomethacin group median 1.9 (range 0-7.8) v. control median 6.5 (2.0-9.1), P=O.OOO4) ( Figure  2 ). Differences remained on day 2 (indomethacin group 4.4, range 0-9.2 v. control group 7.6, range 3.8-9.8, P=0.04) and day 3 (indomethacin group 4.1, range 0-8.6 v. control group 6.0, range 2-10, P=0.058), but they were not statistically significant. There was no We were unable to detect any differences between the groups in uterine cramps and there was no difference in vaginal blood loss, as assessed by midwives' inspection of pads, between the groups on any of the three days. There were no differences between the groups for VAS itch and nausea on any of the study days (Tables 5 and 6 ). There were no episodes of respiratory depression, nor of urinary retention after removal of urinary catheters. 
DISCUSSION
This study has demonstrated that administration of indomethacin suppositories after caesarean delivery performed under spinal anaesthesia produces better postoperative analgesia than subarachnoid morphine alone. Women receiving indomethacin had a significantly longer median time to first analgesia (39 hours v. 9), less pain on movement and less need for supplemental analgesics. The median duration of action of subarachnoid morphine is less than in some other studies, although our subjects were inclined to mobilize early and this may explain the higher pain scores. The range (as reflected by time to first request for oral analgesia) varied from 2 to 82 hours, reflecting interindividual variation. Our findings are in keeping with other studies that suggest the duration of action of subarachnoid morphine is unpredictable and not reliably prolonged-· s • We were particularly concerned to assess pain on movement on the grounds that pain at rest may be minimal, even after major surgery. As Kehlet has pointed out, however, it is only when patients cough or move that the true value of postoperative analgesia can be tested 6
There was no difference in uterine pain scores, despite the anti-prostaglandin action of the drug, but neither was there any difference in uterine blood loss in the 72 hour study period. Nevertheless, it is likely that indomethacin, in addition to its central action, reduces nociceptive input to the spinal cord through its anti-prostaglandin-mediated anti-inflammatory action. The pain on movement VAS scores were similar on all three postoperative days in the control group, whereas the VAS scores on day 1 were much lower in the indomethacin group.
Preoperative administration may be more effective in pre-empting painS but the risks of a sudden premature closure of the fetal ductus arteriosus", although unlikely, made us decide to administer the first dose immediately after the operative procedure. Concerns about adverse effects on neonates were not borne out inasmuch as there were no complications in breast-fed babies reported by the paediatricians caring for them. It is unlikely, however, that any would be detected in such a small sample.
There have been few studies on the effectiveness of NSAIDs for post-caesarean analgesia. Sun et al 10 looked at the effects of varying doses of epidural morphine in combination with IM diclofenac and demonstrated superior analgesia when the two were combined, particularly in respect of uterine pain. In a prior study! \ they found that the combination of lowdose epidural morphine and IM diclofenac led to better analgesia for both uterine and incisional pain.
They also demonstrated that diclofenac alone was inadequate for pain relief.
Bush et aP2 showed an opioid-sparing effect of diclofenac in women undergoing general anaesthesia for caesarean delivery, as judged by patient-controlled administration of papaveretum. They, too, were concerned that a pre-delivery dose night lead to problems in respect of the fetal ductus, and elected to give the single dose after delivery of the baby and before discontinuing anaesthesia. As with our study, there were no untoward effects in the breast-fed babies.
NSAIDs are not without risk and recent experience with newer agents has led to closer scrutiny of these agents. They work principally by interfering with prostaglandin synthesis and therefore have effects on numerous systems. The principal concerns are in respect of haemostasis (bleeding time is prolonged, but not beyond the normal range J3 ), gastric irritation and renal impairment. Some asthmatic patients are sensitive to NSAIDsII. The dosing schedule used here is one devised and used in thousands of patients by one of the authors (TP) over a period of 15 years, apparently without incident. Experience with this schedule has been reported 3 and an identical regimen was reported in 1994 1s , with an observed 50070 reduction in PCA pethidine requirements following open cholecystectomy. However, in the present climate of concern about dose-related side-effects, use of a lower initial dose might be more attractive.
We conclude that rectal indomethacin use for 72 hours following subarachnoid morphine leads to a potentiation of postoperative analgesia after caesarean delivery.
